Oral Hydroxychloroquine Plus Oral Sorafenib to Treat Patients With Refractory or Relapsed Solid Tumors

NCT01634893 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Refractory or Relapsed Solid Tumors

Interventions

DRUG: Sorafenib combined with Hydroxychloroquine

Sponsor

The University of Texas Health Science Center at San Antonio